Dr. Reddy's Laboratories Limited has informed the Exchange about sale of wholly owned subsidiary

Core Business DivestedStrategic Transactions View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1198.00

prior close

₹1210.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+3.9%-4.4% vs market

Pharmaceuticals peers, median of 157sector+2.7%-3.1% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty 100 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

-0.2

15m

-0.0

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4+3.9-4.4+2.7-3.1

Next day

+1.0+3.2-2.2+3.1-2.1

+2.6+4.5-1.9+4.4-1.8

+3.0+3.7-0.6+4.7-1.7

+1.9+5.5-3.6+6.6-4.8

+2.0+5.5-3.6+6.9-4.9

+2.7+6.4-3.7+6.9-4.1

15d

+10.6+4.9+5.7+8.4+2.2

+8.1+6.1+2.0+12.3-4.2

+6.4+1.6+4.8+11.2-4.7

+12.8+4.9+7.9+18.2-5.4

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's Laboratories has sold its entire 100% stake in Svaas Wellness Limited, a wholly owned subsidiary, to Enspirit Technology Services Private Limited for INR 2.23 Crore. The transaction was agreed and completed on April 7, 2026. Svaas Wellness had a turnover of Rs. 28.5 Crore in FY 2025, contributing approximately 0.09% to Dr. Reddy's consolidated turnover. The buyer is a non-related party and is not part of the promoter or group companies. The transaction does not constitute a related party transaction and is not part of any scheme of arrangement.

Likely market impact

This is a relatively small transaction, representing less than 0.1% of consolidated revenue, so the financial impact on Dr. Reddy's is minimal. It signals a strategic pruning of non-core subsidiaries.